Literature DB >> 33649515

Functional CYP3A variants affecting tacrolimus trough blood concentrations in Chinese renal transplant recipients.

Dina Chen1, Huijie Lu1, Weiguo Sui2, Liqing Li1, Jian Xu3, Tengfei Yang1, Siyao Yang1, Ping Zheng4, Yan Chen4, Jiejing Chen2, Wen Xue2, Qingping Li5, Que Zheng1, Demei Ye1, Wolfgang Sadee6, Danxin Wang7, Wanying Qian1, Liusheng Lai2, Chuanjiang Li8, Liang Li9.   

Abstract

The aim of this study was to identify novel genetic variants affecting tacrolimus trough blood concentrations. We analyzed the association between 58 single nucleotide polymorphisms (SNPs) across the CYP3A gene cluster and the log-transformed tacrolimus concentration/dose ratio (log (C0/D)) in 819 renal transplant recipients (Discovery cohort). Multivariate linear regression was used to test for associations between tacrolimus log (C0/D) and clinical factors. Luciferase reporter gene assays were used to evaluate the functions of select SNPs. Associations of putative functional SNPs with log (C0/D) were further tested in 631 renal transplant recipients (Replication cohort). Nine SNPs were significantly associated with tacrolimus log (C0/D) after adjustment for CYP3A5*3 and clinical factors. Dual luciferase reporter assays indicated that the rs4646450 G allele and rs3823812 T allele were significantly associated with increased normalized luciferase activity ratios (p < 0.01). Moreover, CYP3A7*2 was associated with higher TAC log(C0/D) in the group of CYP3A5 expressers. Age, serum creatinine and hematocrit were significantly associated with tacrolimus log (C0/D). CYP3A7*2, rs4646450, and rs3823812 are proposed as functional SNPs affecting tacrolimus trough blood concentrations in Chinese renal transplant recipients. Clinical factors also significantly affect tacrolimus metabolism.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33649515     DOI: 10.1038/s41397-021-00216-w

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  31 in total

1.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.

Authors:  P Kuehl; J Zhang; Y Lin; J Lamba; M Assem; J Schuetz; P B Watkins; A Daly; S A Wrighton; S D Hall; P Maurel; M Relling; C Brimer; K Yasuda; R Venkataramanan; S Strom; K Thummel; M S Boguski; E Schuetz
Journal:  Nat Genet       Date:  2001-04       Impact factor: 38.330

2.  Reduced exposure to calcineurin inhibitors in renal transplantation.

Authors:  Henrik Ekberg; Helio Tedesco-Silva; Alper Demirbas; Stefan Vítko; Björn Nashan; Alp Gürkan; Raimund Margreiter; Christian Hugo; Josep M Grinyó; Ulrich Frei; Yves Vanrenterghem; Pierre Daloze; Philip F Halloran
Journal:  N Engl J Med       Date:  2007-12-20       Impact factor: 91.245

Review 3.  Clinical determinants of calcineurin inhibitor disposition: a mechanistic review.

Authors:  Thomas Vanhove; Pieter Annaert; Dirk R J Kuypers
Journal:  Drug Metab Rev       Date:  2016-02-25       Impact factor: 4.518

4.  Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers.

Authors:  Hui-Lin Tang; Hong-Guang Xie; Yao Yao; Yong-Fang Hu
Journal:  Pharmacogenet Genomics       Date:  2011-11       Impact factor: 2.089

Review 5.  Pharmacogenetics of Membrane Transporters of Tacrolimus in Solid Organ Transplantation.

Authors:  Camille Tron; Florian Lemaitre; Céline Verstuyft; Antoine Petitcollin; Marie-Clémence Verdier; Eric Bellissant
Journal:  Clin Pharmacokinet       Date:  2019-05       Impact factor: 6.447

6.  Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus.

Authors:  Landry K Kamdem; Frank Streit; Ulrich M Zanger; Jürgen Brockmöller; Michael Oellerich; Victor W Armstrong; Leszek Wojnowski
Journal:  Clin Chem       Date:  2005-06-10       Impact factor: 8.327

Review 7.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 8.  Mechanisms of clinically relevant drug interactions associated with tacrolimus.

Authors:  Uwe Christians; Wolfgang Jacobsen; Leslie Z Benet; Alfonso Lampen
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 9.  Drug-metabolizing enzymes CYP3A as a link between tacrolimus and vitamin D in renal transplant recipients: is it relevant in clinical practice?

Authors:  Agnieszka Prytuła; Karlien Cransberg; Ann Raes
Journal:  Pediatr Nephrol       Date:  2018-07-30       Impact factor: 3.714

10.  Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients.

Authors:  Chuan-Jiang Li; Liang Li; Li Lin; Hai-Xia Jiang; Ze-Yan Zhong; Wei-Mo Li; Yan-Jun Zhang; Ping Zheng; Xu-Hui Tan; Lin Zhou
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.